[1] Voruganti S, Yamsani SK, Yamsani MR. Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits[J]. Eur J Drug Metab Pharmacokinet, 2013. [2] Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol[J]. Clin Pharmacol Ther, 2007, 81(5):669-678. [3] Hou YC, Lin SP, Chao PD. Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A[J]. Food Chem, 2012,135(4):2307-2312. [4] Mandery K, Bujok K, Schmidt I, et al. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1[J]. Biochem Pharmacol, 2010,80(11):1746-1753. [5] Zhou F, Zhang J, Li P, et al. Toward a new age of cellular pharmacokinetics in drug discovery[J]. Drug Metab Rev, 2011,43(3):335-345. [6] Zheng Y, Zhou F, Wu X, et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo [J]. J Ethnopharmacol, 2010,128(3):615-622. [7] Zhang J, Zhou F, Wu X, et al. Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells[J]. Br J Pharmacol, 2012,165(1):120-134. [8] Zhang DM, He ZW, Liu XD, et al. In-vivo and in-vitro studies on the effect of Huang-Lian-Jie-Du-Tang on nimodipine transport across rat blood-brain barrier[J]. J Pharm Pharmacol, 2007,59(12):1733-1738. [9] Taki Y, Yokotani K, Yamada S, et al. Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice[J]. Phytomedicine, 2012,19(2):177-182. [10] Malati CY, Robertson SM, Hunt JD, et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants[J]. J Clin Pharmacol, 2012,52(6):932-939. [11] Goey AK, Meijerman I, Rosing H, et al. The effect of St John's wort on the pharmacokinetics of docetaxel[J]. Clin Pharmacokinet, 2014,53(1):103-110. [12] Xia CH, Sun JG, Wang GJ, et al. Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats[J]. Planta Med, 2010,76(3):245-250. [13] Yamaura K, Shimada M, Nakayama N, et al. Protective effects of goldenseal (Hydrastis canadensis L.) on acetaminophen-induced hepatotoxicity through inhibition of CYP2E1 in rats[J]. Pharmacognosy Res, 2011,3(4):250-255. [14] Hao H, Zheng X, Li P, et al. Translational research insights into pharmacokinetic herb-drug interactions[J]. Curr Drug Metab, 2011,12(9):850-870. [15] Na DH, Ji HY, Park EJ, et al. Evaluation of metabolism-mediated herb-drug interactions[J]. Arch Pharm Res, 2011,34(11):1829-1842. [16] Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics[J]. Clin Pharmacol Ther, 2005,78(1):25-33. [17] Lai L, Hao H, Wang Q, et al. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats[J]. Drug metab Dispos, 2009,37(12):2399-2407. [18] Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies[J]. Clin Pharmacokinet, 2007,46(12):1039-1049. [19] Xu R, Zhang X, Yang J, et al. Effects of glycyrrhizin on biliary transport and hepatic levels of glutathione in rats[J]. Biopharm Drug Dispos, 2012,33(5):235-245. [20] de Lima Toccafondo Vieira M, Huang SM. Botanical-drug interactions: a scientific perspective[J]. Planta Med, 2012,78(13):1400-1415. [21] Alissa EM. Medicinal Herbs and Therapeutic Drugs Interactions[J]. Ther Drug Monit, 2014. [22] Brantley SJ, Argikar AA, Lin YS, et al. Herb-drug interactions: challenges and opportunities for improved predictions[J]. Drug Metab Dispos, 2014,42(3):301-317. [23] Yan Z, Caldwell GW. In vitro identification of cytochrome P450 enzymes responsible for drug metabolism[J]. Methods Mol Biol, 2013,1015:251-261. [24] Kwatra D, Budda B, Vadlapudi AD, et al. Transfected MDCK cell line with enhanced expression of CYP3A4 and glycoprotein as a model to study their role in drug transport and metabolism[J]. Mol Pharm, 2012,9(7):1877-1886. [25] Vieira ML, Zhao P, Berglund EG, et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor[J]. Clin Pharmacol Ther, 2012,91(4):700-708. [26] Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review[J]. Clin Pharmacol Ther, 2011,89(2):259-267. [27] Khalil F, Laer S. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development[J]. J Biomed, 2011,2011:907461. [28] Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy[J]. Clin Cancer Res, 2010,16(5):1442-1451. [29] Moro M, Bertolini G, Tortoreto M, et al. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells[J]. J Biomed Biotechnol,2012,2012:568567. [30] Stewart NA, Buch SC, Conrads TP, et al. A UPLC-MS/MS assay of the “Pittsburgh cocktail”: six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution[J]. Analyst, 2011,136(3):605-612. [31] Chen XW, Sneed KB, Pan SY, et al. Herb-drug interactions and mechanistic and clinical considerations[J]. Curr Drug Metab, 2012,13(5):640-651. [32] Videau O, Delaforge M, Levi M, et al. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans[J]. Rapid Commun Mass Spectrom, 2010,24(16):2407-2419. [33] Videau O, Pitarque S, Troncale S, et al. Can a cocktail designed for phenotyping pharmacokinetics and metabolism enzymes in human be used efficiently in rat [J] ? Xenobiotica, 2012,42(4):349-354. [34] Gurley BJ. Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements[J]. Planta Med, 2012,78(13):1478-1489. [35] Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling[J]. Clin Pharmacol Ther, 2007,81(2):298-304. [36] 陈群, 徐喆, 孙华, 等. 孕烷X受体生物特性及其在药物代谢中的作用研究进展[J]. 中国临床药理学与治疗学, 2013,18(3):241-246. [37] Wu JJ, Ai CZ, Liu Y, et al. Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes[J]. Curr Drug Metab, 2012,13(5):599-614. [38] Zhang J, Zhou F, Lu M, et al. Pharmacokinetics-pharmacology disconnection of herbal medicines and its potential solutions with cellular pharmacokinetic-pharmacodynamic strategy[J]. Curr Drug Metab, 2012,13(5):558-576. |